1162656-22-5
1162656-22-5 結(jié)構(gòu)式
基本信息
4-乙基-2,6-雙(吡啶-3-基亞甲基)環(huán)己酮
(2E,6E)-4-乙基-2,6-二(3-吡啶基亞甲基)環(huán)己酮
MCB-613
4-ethyl-2,6-bis(pyridin-3-ylmethylene)cyclohexanone
(2E,6E)-4-Ethyl-2,6-bis(3-pyridinylmethylene)cyclohexanone
Cyclohexanone, 4-ethyl-2,6-bis(3-pyridinylmethylene)-, (2E,6E)-
(2E,6E)-4-ethyl-2,6-bis(pyridin-3-ylmethylidene)cyclohexan-1-one
物理化學(xué)性質(zhì)
常見問題列表
MCB-613 (6-8 μM; 24 hours) activates endogenous MMP13 mRNA expression in MDA-MB-231 cells. MCB-613 (2-10 μM; 4 hours) leads to proteasome dysfunction and ER stress, the induction of the markers for unfolded protein response (UPR), including the phosphorylation of eIF2α and IRE1α as well as the induction of ATF4 protein expression. MCB-613 (0-7 μM; 4 hours) affects SRC-3 KO and WT HeLa cell viability, SRC-3 WT HeLa cell is more affected by MCB-613 compared with KO cells.
RT-PCR
| Cell Line: | MDA-MB-231 cells |
| Concentration: | 6 μM; 8 μM |
| Incubation Time: | 24 hours |
| Result: | Increased MMP13 mRNA expression. |
Western Blot Analysis
| Cell Line: | HeLa cells |
| Concentration: | 2 μM; 4 μM; 6 μM; 8 μM; 10 μM |
| Incubation Time: | 24 hours |
| Result: | Induced the p-eIF2α, p-IRE1α, and ATF-4 protein expression. |
Cell Viability Assay
| Cell Line: | SRC-3 KO and WT HeLa cells |
| Concentration: | 3 μM; 4 μM; 5 μM; 6 μM; 7 μM |
| Incubation Time: | 24 hours |
| Result: | Decreased SRC-3 KO and WT HeLa cell viability. |
MCB-613 (intravenous injection; 20 mg/kg; 3 times/week; 7 weeks) significantly and dramatically stalls the growth of the tumor compared with the control group and causes no obvious animal toxicity
| Animal Model: | MCF-7 breast cancer mouse xenograft model (athymic nude mice by injecting MCF-7 cells into mammary fat pads) |
| Dosage: | 20 mg/kg |
| Administration: | Intravenous injection; 20 mg/kg; 3 times/week; 7 weeks |
| Result: | Inhibited tumor growth in vivo. |